Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19582838.
- Also identified by DOI 10.1002/jbm.a.32560.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this study was to determine the effects of alendronate (ALN) on osteoclastic resorption of beta-tricalcium phosphate (beta-TCP) and bone formation. beta-TCP blocks of 75% porosity, with or without ALN treatment, were implanted into cavities drilled in rabbit femoral condyles. New bone formation, residual amount of beta-TCP, and the number of tartrate-resistant acid phosphatase-positive cells were evaluated 2 weeks after surgery. The results show that local application of ALN at a concentration of 10(-2) to 10(-6)M reduced the number of osteoclasts on the surface of beta-TCP. New bone formation was also inhibited by ALN in a dose-dependent manner. Thus, inhibition of osteoclast formation resulted in reduced beta-TCP resorption and bone formation. These results suggest that osteoclast-mediated resorption plays an important role in bone formation and a coupling-like phenomenon could occur in beta-TCP-filled bone defects.
Medical subject headings
- Alendronate
- Bone Density Conservation Agents
- Bone Resorption
- Bone and Bones
- Calcium Phosphates
- Osteoclasts
- Osteogenesis